Tag:

AstraZeneca

Latest Headlines

Latest Headlines

Pictures tell the story in AstraZeneca's breast cancer photo-sharing push

Pharma companies are no stranger to photography-based disease awareness campaigns. But there's something different about AstraZeneca's latest breast cancer photo campaign: The photographers are the patients themselves.

UPDATED: Texas AG: AstraZeneca paid $465K in kickbacks, committed fraud in Seroquel marketing

Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.

With help from Charles River, AstraZeneca expands its respiratory pipeline

AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.

AstraZeneca finally bails on troubled Targacept after years of failure

After 9 years of fruitless work on treatments for Alzheimer's disease and depression, AstraZeneca is dissolving its partnership with Targacept, leaving the battered biotech to pick up the pieces of its dwindling pipeline.

AstraZeneca touts upbeat asthma data for key respiratory candidate

It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.

AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster

After acknowledging a midstage setback for its key respiratory drug benralizumab in COPD last month, AstraZeneca's big MedImmune division has come back with positive, though somewhat mixed, Phase IIb data underscoring the effectiveness of knocking down eosinophils--white blood cells--in preventing asthma attacks.

AstraZeneca crows about Brilinta edge in new ACS treatment guidelines

Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really could become a blockbuster, the CEO figures. No, really.

AstraZeneca partner Ardelyx scores a trial success for GI drug

Fresh off an IPO, Ardelyx reports that its lead drug tenapanor (RDX5791) scored a success in a large Phase IIb trial for irritable bowel syndrome. And that counts as a win for AstraZeneca, which signed a $272 million partnership deal on the drug back in 2012--part of a deal frenzy aimed at repairing a damaged pipeline.

AstraZeneca moves away from outsourcing, at least in IT

AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.

ESMO: Bristol-Myers, Roche, AstraZeneca, GSK, Merck jostle for spotlight

Over the weekend oncology investigators from all around the world gathered in Madrid at the European Society for Medical Oncology (ESMO) 2014 Congress to review the latest advances--and setbacks--in the fast-moving field of cancer drug research. As usual, the big companies dominated the discussions, as rival oncology groups touted new data as they tried to position competing therapies in the global scramble to develop new and better cancer drugs, now one of the hottest fields in R&D.